

# Aggressive Fund

Portfolio Investment Entity

Monthly Fact Sheet as at 31 August 2022



## Portfolio Managers



**Stephen Johnston**  
Portfolio Manager



**Jonathan Windust**  
Co-Portfolio Manager

The Fund fell 1.6% in August. After a promising start to the month, we saw a global sell-off in share markets, following a speech from Jerome Powell, the Chair of the US Federal Reserve, where he made it clear he is committed to getting inflation under control, despite signs that economic growth is slowing.

In our international portfolio, commodity related names outperformed despite weakness seen in the price of oil and other commodities. The top contributor in August was energy company Shell (+6.1%). One of the attractions of Shell is their commitment to carbon reduction. Encouragingly, Shell has made large investments in renewable energy including wind, solar and hydrogen as well as vehicle charging infrastructure. US healthcare insurer Elevance Health (+1.7%) was another standout, proving its defensive qualities in a tough month for shares. Other highlights included financial giant Charles Schwab (+3.1%) a key beneficiary of higher interest rates and Cheniere Energy (+7.3%) one of the largest LNG producers in the world benefitting from high natural gas prices.

Underperformers in August were semiconductor company Analog Devices (-11.4%) on concerns of slower demand ahead and pharmaceutical company Bristol Myers (-8.6%) on a mixed data readout from a next generation anticoagulant drug trial. We continue to remain positive on both companies over the medium term.


Closer to home, Australasian markets outperformed in August. Strong performers included Australian miner IGO (+21.7%), a key supplier of both lithium and nickel which are essential as the world transitions to electric vehicles and renewable energy. BHP Group (+5.0%) and Santos (+9.7%) also had a solid month. In the New Zealand market, Infratil (+8.0%) outperformed and after a challenging period, a2 Milk (+24.8%) soared, on strong full year results as infant formula sales recovered.

Looking ahead, we remain cautious for now and are holding higher levels of cash until we see a sustained decline in inflation.

To view Milford's September 2022 Market and Economic Review please see [milfordasset.com/fact-sheet](https://milfordasset.com/fact-sheet).

## Cumulative Fund Performance

(after fees and before tax)



Assumes the growth of \$10,000 invested at the Fund's inception date.

## Key Fund Facts

<b>Objective</b> <sup>2</sup>	To maximise capital growth over the minimum recommended investment timeframe
<b>Description</b>	Primarily invests in international equities, with a moderate allocation to Australasian equities

<b>Minimum recommended investment timeframe</b>	10 years +
<b>Target Allocation</b>	5% Income Assets / 95% Growth Assets
<b>Neutral FX Exposure</b>	24.5%
<b>Net Asset Value (NAV)</b>	\$918.6 M
<b>Buy-sell Spread</b>	None - swing pricing applies (See PDS for details)
<b>Inception Date</b>	21 June 2021
<b>Benchmark</b>	Not applicable
<b>Base Fund Fee</b> <sup>3</sup>	1.15%
<b>Performance Fee</b>	The Fund may invest into related Milford funds that charge performance fees.
<b>Total Fund Fees</b> <sup>4</sup>	1.15%

<b>Risk Indicator</b>	Lower risk	1	2	3	4	5	6	7	Higher risk
		Potentially lower returns				Potentially higher returns			



## Aggressive Fund as at 31 August 2022

### Investment Performance after fees as at 31 August 2022<sup>5</sup>

Unit Price: \$0.9492

	1 Month	3 Months	1 year	3 years (p.a.)	5 years (p.a.)	Since inception (p.a.)
Milford Aggressive Fund (Gross Of Tax)	-1.57%	-1.06%	-10.35%	-	-	-4.13%
After Tax 10.50%	-1.53%	-1.04%	-10.42%	-	-	-4.33%
After Tax 17.50%	-1.51%	-1.02%	-10.47%	-	-	-4.47%
After Tax 28.00%	-1.48%	-1.01%	-10.54%	-	-	-4.67%
Market Index <sup>1</sup>	-1.77%	-2.03%	-7.64%	-	-	-2.29%

### Top Security Holdings

Holdings	% of Fund
Elevance Health	2.82%
Boston Scientific	2.67%
Shell	2.48%
Bristol-Myers Squibb	2.18%
Aon	2.06%
Alphabet	1.94%
Intuit	1.85%
Charles Schwab	1.83%
Microsoft	1.81%
Danaher	1.78%

### Current Asset Allocation


	Actual Investment Mix	Neutral Investment Mix
Effective Cash <sup>#</sup>	16.02%	5.0%
New Zealand Fixed Interest	0.16%	0.0%
International Fixed Interest	0.00%	0.0%
New Zealand Equities	5.76%	5.0%
Australian Equities	15.52%	20.0%
International Equities	62.54%	70.0%
Other	0.00%	0.0%

<sup>#</sup> The actual cash held by the Fund is 13.21%. Effective Cash reported above is adjusted to reflect the Fund's notional positions (e.g. derivatives used to increase or reduce market exposure).

### Sector Allocation

Allocation	Weight %
Health Care	15.36%
Financials	12.10%
Information Technology	10.95%
Industrials	9.16%
Consumer Discretionary	8.26%
Energy	7.97%
Communication Services	5.44%
Utilities	4.22%
Other Sectors	10.52%
Cash and Other	16.02%

### Region Exposure



1. The Fund does not have a performance benchmark, hence a market index has been included for comparison purposes. See the Statement of Investment Policy and Objectives for more details on the market index. The market index is a blend of indices that represent the Fund's neutral asset allocation. Note the Fund's investment strategy is designed to achieve its objective, which may mean that at times, the returns of the market index may not be an appropriate measure. 2. After the base fund fee but before tax and before the performance fee. 3. Where applicable, the Base Fund Fee includes an estimate of non-related underlying fund charges. 4. The Total Fund Fees comprise the Base Fund Fee and any estimated Performance Fee. Please refer to the Product Disclosure Statement for more information as to how these are calculated. 5. Please note past performance is not a guarantee of future returns.

Please refer to the 'Glossary for the Monthly Fact Sheet' at [milfordasset.com/fact-sheet-ks](http://milfordasset.com/fact-sheet-ks) for more information about the data published within this document.

Disclaimer: The Milford Fund Fact Sheet has been prepared by Milford Funds Limited. It is based on information believed to be accurate and reliable although no guarantee can be given that this is the case. No reproduction of any material either in part or in full is permitted without prior permission. For more information about the Fund, please refer to the Production Disclosure Statement or the latest Quarterly Fund Update.